Fate Therapeutics (FATE) News Today $1.88 -0.12 (-6.00%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short InterestFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 11,350,000 shares, a growth of 9.2% from the November 15th total of 10,390,000 shares. Based on an average daily volume of 2,250,000 shares, the short-interest ratio is currently 5.0 days.December 17 at 9:20 AM | marketbeat.comBarclays Gives a Buy Rating to Fate Therapeutics (FATE)December 12, 2024 | markets.businessinsider.comHold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy DevelopmentDecember 11, 2024 | markets.businessinsider.comFate Therapeutics presents new data from FT819 studyDecember 10, 2024 | markets.businessinsider.comFate Therapeutics presents new data from FT819 studyDecember 10, 2024 | markets.businessinsider.comFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus ErythematosusDecember 9, 2024 | globenewswire.comPiper Sandler Remains a Buy on Fate Therapeutics (FATE)December 6, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)December 6, 2024 | markets.businessinsider.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average recommendation of "Hold" from the ten brokerages that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a buy recommDecember 3, 2024 | marketbeat.comFate Therapeutics, Inc.: Fate Therapeutics Announces Leadership TransitionNovember 30, 2024 | finanznachrichten.deFate Therapeutics Taps Bob Valamehr to Be CEONovember 29, 2024 | marketwatch.comFate Therapeutics CEO Wolchko to retireNovember 29, 2024 | markets.businessinsider.comFate Therapeutics Announces Leadership TransitionNovember 29, 2024 | globenewswire.comVestal Point Capital LP Has $5.90 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Vestal Point Capital LP lowered its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 15.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,685,000 shares of the biopharmaceutical company's stock after seNovember 29, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Short Interest UpdateFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 10,390,000 shares, a drop of 34.7% from the October 31st total of 15,900,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the short-interest ratio is currently 5.4 days.November 29, 2024 | marketbeat.comFate Therapeutics to Present at Upcoming December Investor ConferencesNovember 26, 2024 | globenewswire.comFate Therapeutics' SWOT analysis: clinical progress boosts stock outlookNovember 23, 2024 | uk.investing.comPositive Clinical Developments and Promising Outcomes Propel Fate Therapeutics’ Growth PotentialNovember 21, 2024 | markets.businessinsider.comBarclays Releases a Buy Rating on Fate Therapeutics (FATE)November 20, 2024 | markets.businessinsider.comFate stock closes 12% higher after soaring 73% on drug data (update)November 20, 2024 | msn.comFate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment OptionsNovember 20, 2024 | seekingalpha.comStifel ‘impressed’ with results for Fate Therapeutics’ first FT819 LN patientNovember 19, 2024 | markets.businessinsider.comFate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trialNovember 19, 2024 | markets.businessinsider.comFate stock rallies 37% on positive Phase 1 data for FT819, FT522November 19, 2024 | msn.comFate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR ConvergenceNovember 19, 2024 | finance.yahoo.comWall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug DataNovember 19, 2024 | seekingalpha.comNeedham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE)Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comFate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR ConvergenceNovember 18, 2024 | globenewswire.comFY2024 EPS Estimate for Fate Therapeutics Lowered by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Wedbush reduced their FY2024 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that thNovember 15, 2024 | marketbeat.comFate Therapeutics Unveils Q3 2024 Financial HighlightsNovember 14, 2024 | markets.businessinsider.comOptimistic Outlook for Fate Therapeutics Amid Promising Cell Therapy DevelopmentsNovember 14, 2024 | markets.businessinsider.comCautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial StabilityNovember 14, 2024 | markets.businessinsider.comFate Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 14, 2024 | finance.yahoo.comAnalysts Are Neutral on These Healthcare Stocks: Fate Therapeutics (FATE), BridgeBio Pharma (BBIO)November 13, 2024 | markets.businessinsider.comConservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive EdgeNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (FATE) Receives a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comFate Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 12, 2024 | globenewswire.comFate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual MeetingNovember 9, 2024 | globenewswire.comFate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual MeetingNovember 8, 2024 | globenewswire.comFate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average - Here's WhyFate Therapeutics (NASDAQ:FATE) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?November 8, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by BrokeragesFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has received an average rating of "Hold" from the twelve analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fourNovember 8, 2024 | marketbeat.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been given an average rating of "Hold" by the twelve analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendaOctober 14, 2024 | marketbeat.comDimensional Fund Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Dimensional Fund Advisors LP raised its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 100.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,130,280 shares ofOctober 9, 2024 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comRenaissance Technologies LLC Takes $1.80 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)Renaissance Technologies LLC acquired a new position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 548,544 shares of the biopharmaceutical company'October 4, 2024 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)October 2, 2024 | globenewswire.comPerceptive Advisors LLC Invests $1.13 Million in Fate Therapeutics, Inc. (NASDAQ:FATE)Perceptive Advisors LLC acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 345,575 shares ofSeptember 30, 2024 | marketbeat.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address A conspiracy Trump won’t unseal (Ad)New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous. This is the untold, true story of God’s Investment. FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.250.75▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼44▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvation Bio News ArriVent BioPharma News Immatics News Replimune Group News uniQure News 89bio News Pliant Therapeutics News Relay Therapeutics News Anavex Life Sciences News Immunome News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts